Europe cannot afford to rely on external nations for essential medicines and active pharmaceutical ingredients, according to European Parliament Health Committee delegates meeting in Athens. European Parliament lawmaker Ignazio Marino led a delegation meeting with Greece’s Minister of Health to address the continent’s heavy reliance on foreign pharmaceutical supply chains and secure long-term access to treatments for citizens.
European Pharmaceutical Autonomy: EU Health Leaders Push for Domestic Production of Active Ingredients
Addressing Foreign Supply Dependency in the EU
The European Union faces strategic vulnerabilities due to its reliance on third countries for basic drug components and raw materials. Greece possesses an established pharmaceutical sector, particularly in generic drug manufacturing, positioning the nation to contribute significantly to broader European autonomy goals. Lawmakers emphasize that pharmaceutical security is a fundamental component of overall public safety, ensuring patients maintain uninterrupted access to necessary therapies without risking supply bottlenecks.
Investing in Future European Pharmaceutical Hubs
Beyond securing current supply lines, EU health officials stress the necessity of investing in dedicated European pharmaceutical hubs. These integrated centers aim to combine academic research, technological innovation, and large-scale manufacturing in a single framework. By fostering localized development, the EU intends to study, develop, and produce the next generation of innovative medicines entirely within member states.
Frequently Asked Questions
- Why is the European Union focusing on pharmaceutical autonomy? EU health officials aim to eliminate critical vulnerabilities tied to foreign supply chains that provide essential medicines and active pharmaceutical ingredients.
- What role does Greece play in this initiative? Greece features an established pharmaceutical industry with specific strengths in generic drug production, offering a viable foundation for expanded European manufacturing networks.
- How do officials plan to address future medical needs? Lawmakers advocate for specialized European hubs that integrate scientific research, technological innovation, and commercial production for advanced therapeutics.
Related reading